UNLABELLED: Studies in rats showed that the pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)(3)-nitrilotriacetic acid, (99m)Tc(CO)(3)(NTA), were essentially identical to those of (131)I ortho-iodohippuran ((131)I-OIH), the clinical gold standard for the measurement of effective renal plasma flow. Our objective was to compare the pharmacokinetics of these 2 tracers in healthy volunteers. METHODS: (99m)Tc(CO)(3)(NTA) was prepared with commercially available NTA and a commercially available kit and isolated by reversed-phase high-performance liquid chromatography. Approximately 74 MBq (2 mCi) of (99m)Tc(CO)(3)(NTA) were coinjected with 9.25 MBq (250 microCi) of (131)I-OIH in 9 volunteers, and simultaneous imaging of each tracer was performed for 24 min. Plasma clearances were determined from 8 blood samples obtained 3-90 min after injection using the single-injection, 2-compartment model. Plasma protein binding, red cell uptake, and percentage injected dose in the urine at 30 and 180 min were determined. RESULTS: There was no difference in the plasma clearances of (99m)Tc(CO)(3)(NTA) and (131)I-OIH, 475 +/- 105 mL/min versus 472 +/- 108 mL/min, respectively. The plasma protein binding and red cell uptake of (99m)Tc(CO)(3)(NTA) were 43% +/- 5% and 9% +/- 6%, respectively; both values were significantly lower (P < 0.001) than the plasma protein binding (75% +/- 3%) and red cell uptake (17% +/- 5%) of (131)I-OIH. There was no significant difference in the percentage injected dose recovered in the urine at 30 min and at 3 h; for comparison, the percentage dose in the urine at 3 h was 91% +/- 4% for (99m)Tc(CO)(3)(NTA) and 91% +/- 6% for (131)I-OIH (P = 0.96). Image quality with (99m)Tc(CO)(3)(NTA) was excellent, and the renogram parameters were similar to those of (131)I-OIH. CONCLUSION: Preliminary results in healthy volunteers suggest that the pharmacokinetic behavior of (99m)Tc(CO)(3)(NTA) is comparable to that of (131)I-OIH.
UNLABELLED: Studies in rats showed that the pharmacokinetics of the tricarbonyl core radiopharmaceutical (99m)Tc(CO)(3)-nitrilotriacetic acid, (99m)Tc(CO)(3)(NTA), were essentially identical to those of (131)I ortho-iodohippuran ((131)I-OIH), the clinical gold standard for the measurement of effective renal plasma flow. Our objective was to compare the pharmacokinetics of these 2 tracers in healthy volunteers. METHODS: (99m)Tc(CO)(3)(NTA) was prepared with commercially available NTA and a commercially available kit and isolated by reversed-phase high-performance liquid chromatography. Approximately 74 MBq (2 mCi) of (99m)Tc(CO)(3)(NTA) were coinjected with 9.25 MBq (250 microCi) of (131)I-OIH in 9 volunteers, and simultaneous imaging of each tracer was performed for 24 min. Plasma clearances were determined from 8 blood samples obtained 3-90 min after injection using the single-injection, 2-compartment model. Plasma protein binding, red cell uptake, and percentage injected dose in the urine at 30 and 180 min were determined. RESULTS: There was no difference in the plasma clearances of (99m)Tc(CO)(3)(NTA) and (131)I-OIH, 475 +/- 105 mL/min versus 472 +/- 108 mL/min, respectively. The plasma protein binding and red cell uptake of (99m)Tc(CO)(3)(NTA) were 43% +/- 5% and 9% +/- 6%, respectively; both values were significantly lower (P < 0.001) than the plasma protein binding (75% +/- 3%) and red cell uptake (17% +/- 5%) of (131)I-OIH. There was no significant difference in the percentage injected dose recovered in the urine at 30 min and at 3 h; for comparison, the percentage dose in the urine at 3 h was 91% +/- 4% for (99m)Tc(CO)(3)(NTA) and 91% +/- 6% for (131)I-OIH (P = 0.96). Image quality with (99m)Tc(CO)(3)(NTA) was excellent, and the renogram parameters were similar to those of (131)I-OIH. CONCLUSION: Preliminary results in healthy volunteers suggest that the pharmacokinetic behavior of (99m)Tc(CO)(3)(NTA) is comparable to that of (131)I-OIH.
Authors: I Gordon; P Colarinha; J Fettich; S Fischer; J Frökier; K Hahn; L Kabasakal; M Mitjavila; P Olivier; A Piepsz; U Porn; R Sixt; J van Velzen Journal: Eur J Nucl Med Date: 2001-03
Authors: A Taylor; A Manatunga; K Morton; L Reese; F S Prato; E Greenberg; R Folks; B J Kemp; M E Jones; P E Corrigan; J Galt; L Eshima Journal: Radiology Date: 1997-07 Impact factor: 11.105
Authors: Malgorzata Lipowska; Haiyang He; Eugene Malveaux; Xiaolong Xu; Luigi G Marzilli; Andrew Taylor Journal: J Nucl Med Date: 2006-06 Impact factor: 10.057
Authors: Haiyang He; Malgorzata Lipowska; Anna Maria Christoforou; Luigi G Marzilli; Andrew T Taylor Journal: Nucl Med Biol Date: 2007-08 Impact factor: 2.408
Authors: Pramuditha L Abhayawardhana; Patricia A Marzilli; Frank R Fronczek; Luigi G Marzilli Journal: Inorg Chem Date: 2014-01-08 Impact factor: 5.165
Authors: Malgorzata Lipowska; Haiyang He; Xiaolong Xu; Andrew T Taylor; Patricia A Marzilli; Luigi G Marzilli Journal: Inorg Chem Date: 2010-04-05 Impact factor: 5.165
Authors: Jeffrey Klenc; Malgorzata Lipowska; Pramuditha L Abhayawardhana; Andrew T Taylor; Luigi G Marzilli Journal: Inorg Chem Date: 2015-06-12 Impact factor: 5.165
Authors: Malgorzata Lipowska; Nashwa Jarkas; Ronald J Voll; Jonathon A Nye; Jeffrey Klenc; Mark M Goodman; Andrew T Taylor Journal: Nucl Med Biol Date: 2017-12-27 Impact factor: 2.408
Authors: Brian M Zeglis; Jacob L Houghton; Michael J Evans; Nerissa Viola-Villegas; Jason S Lewis Journal: Inorg Chem Date: 2013-12-06 Impact factor: 5.165
Authors: Theshini Perera; Pramuditha Abhayawardhana; Patricia A Marzilli; Frank R Fronczek; Luigi G Marzilli Journal: Inorg Chem Date: 2013-02-19 Impact factor: 5.165